{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:51:09Z","timestamp":1794009069785,"version":"4.8.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS097594"],"award-info":[{"award-number":["R01NS097594"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM116387"],"award-info":[{"award-number":["R35GM116387"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The OX<jats:sub>2<\/jats:sub> orexin receptor (OX<jats:sub>2<\/jats:sub>R) is a highly expressed G protein-coupled receptor (GPCR) in the brain that regulates wakefulness and circadian rhythms in humans. Antagonism of OX<jats:sub>2<\/jats:sub>R is a proven therapeutic strategy for insomnia drugs, and agonism of OX<jats:sub>2<\/jats:sub>R is a potentially powerful approach for narcolepsy type 1, which is characterized by the death of orexinergic neurons. Until recently, agonism of OX<jats:sub>2<\/jats:sub>R had been considered \u2018undruggable.\u2019 We harness cryo-electron microscopy of OX<jats:sub>2<\/jats:sub>R-G protein complexes to determine how the first clinically tested OX<jats:sub>2<\/jats:sub>R agonist TAK-925 can activate OX<jats:sub>2<\/jats:sub>R in a highly selective manner. Two structures of TAK-925-bound OX<jats:sub>2<\/jats:sub>R with either a G<jats:sub>q<\/jats:sub> mimetic or G<jats:sub>i<\/jats:sub> reveal that TAK-925 binds at the same site occupied by antagonists, yet interacts with the transmembrane helices to trigger activating microswitches. Our structural and mutagenesis data show that TAK-925\u2019s selectivity is mediated by subtle differences between OX<jats:sub>1<\/jats:sub> and OX<jats:sub>2<\/jats:sub> receptor subtypes at the orthosteric pocket. Finally, differences in the polarity of interactions at the G protein binding interfaces help to rationalize OX<jats:sub>2<\/jats:sub>R\u2019s coupling selectivity for G<jats:sub>q<\/jats:sub> signaling. The mechanisms of TAK-925\u2019s binding, activation, and selectivity presented herein will aid in understanding the efficacy of small molecule OX<jats:sub>2<\/jats:sub>R agonists for narcolepsy and other circadian disorders.<\/jats:p>","DOI":"10.1038\/s41467-022-30601-3","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T10:04:07Z","timestamp":1653473047000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Molecular mechanism of the wake-promoting agent TAK-925"],"prefix":"10.1038","volume":"13","author":[{"given":"Jie","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyong","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron P.","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Sjodt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsutoshi","family":"Okabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuki","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Miyanohana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rameshu","family":"Rallabandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4234-5686","authenticated-orcid":false,"given":"Xiaochen","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4602-836X","authenticated-orcid":false,"given":"Mack","family":"Flinspach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8816-5798","authenticated-orcid":false,"given":"Jef K.","family":"De Brabander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7174-4993","authenticated-orcid":false,"given":"Daniel M.","family":"Rosenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,25]]},"reference":[{"key":"30601_CR1","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/bph.12415","volume":"171","author":"J Li","year":"2014","unstructured":"Li, J., Hu, Z. & Lecea, Lde The hypocretins\/orexins: integrators of multiple physiological functions. Br. J. Pharmacol. 171, 332\u2013350 (2014).","journal-title":"Br. J. Pharmacol."},{"key":"30601_CR2","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.tips.2006.05.006","volume":"27","author":"JM Zeitzer","year":"2006","unstructured":"Zeitzer, J. M., Nishino, S. & Mignot, E. The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions. Trends Pharm. Sci. 27, 368\u2013374 (2006).","journal-title":"Trends Pharm. Sci."},{"key":"30601_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1756-6606-1-19","volume":"1","author":"OJ Marston","year":"2008","unstructured":"Marston, O. J. et al. Circadian and dark-pulse activation of orexin\/hypocretin neurons. Mol. Brain 1, 19\u201319 (2008).","journal-title":"Mol. Brain"},{"key":"30601_CR4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1146\/annurev-pharmtox-010510-100528","volume":"51","author":"TE Scammell","year":"2011","unstructured":"Scammell, T. E. & Winrow, C. J. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev. Pharm. 51, 243\u2013266 (2011).","journal-title":"Annu Rev. Pharm."},{"key":"30601_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41582-019-0226-9","volume":"15","author":"CLA Bassetti","year":"2019","unstructured":"Bassetti, C. L. A. et al. Narcolepsy \u2014 clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat. Rev. Neurol. 15, 519\u2013539 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"30601_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/sleep\/25.2.197","volume":"25","author":"MH Silber","year":"2002","unstructured":"Silber, M. H., Krahn, L. E., Olson, E. J. & Pankratz, V. S. The epidemiology of narcolepsy in olmsted county, minnesota: a population-based study. Sleep 25, 197\u2013202 (2002).","journal-title":"Sleep"},{"key":"30601_CR7","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/79690","volume":"6","author":"C Peyron","year":"2000","unstructured":"Peyron, C. et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 6, 991\u2013997 (2000).","journal-title":"Nat. Med."},{"key":"30601_CR8","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/archneur.59.10.1553","volume":"59","author":"E Mignot","year":"2002","unstructured":"Mignot, E. et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch. Neurol. Chic. 59, 1553\u20131562 (2002).","journal-title":"Arch. Neurol. Chic."},{"key":"30601_CR9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0092-8674(00)81973-X","volume":"98","author":"RM Chemelli","year":"1999","unstructured":"Chemelli, R. M. et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98, 437\u2013451 (1999).","journal-title":"Cell"},{"key":"30601_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0896-6273(01)00293-8","volume":"30","author":"J Hara","year":"2001","unstructured":"Hara, J. et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30, 345\u2013354 (2001).","journal-title":"Neuron"},{"key":"30601_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0092-8674(00)81965-0","volume":"98","author":"L Lin","year":"1999","unstructured":"Lin, L. et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98, 365\u2013376 (1999).","journal-title":"Cell"},{"key":"30601_CR12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S0896-6273(03)00330-1","volume":"38","author":"JT Willie","year":"2003","unstructured":"Willie, J. T. et al. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron 38, 715\u2013730 (2003).","journal-title":"Neuron"},{"key":"30601_CR13","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/bph.12639","volume":"172","author":"C Baimel","year":"2015","unstructured":"Baimel, C. et al. Orexin\/hypocretin role in reward: implications for opioid and other addictions. Brit J. Pharm. 172, 334\u2013348 (2015).","journal-title":"Brit J. Pharm."},{"key":"30601_CR14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1146\/annurev-pharmtox-010716-104837","volume":"57","author":"PJ Coleman","year":"2016","unstructured":"Coleman, P. J., Gotter, A. L., Herring, W. J., Winrow, C. J. & Renger, J. J. The discovery of suvorexant, the first orexin receptor drug for insomnia. Annu Rev. Pharm. 57, 509\u2013533 (2016).","journal-title":"Annu Rev. Pharm."},{"key":"30601_CR15","doi-asserted-by":"publisher","first-page":"4761","DOI":"10.1016\/j.bmcl.2013.06.057","volume":"23","author":"TP Lebold","year":"2013","unstructured":"Lebold, T. P., Bonaventure, P. & Shireman, B. T. Selective orexin receptor antagonists. Bioorg. Medicinal Chem. Lett. 23, 4761\u20134769 (2013).","journal-title":"Bioorg. Medicinal Chem. Lett."},{"key":"30601_CR16","doi-asserted-by":"publisher","first-page":"7931","DOI":"10.1021\/acs.jmedchem.5b00988","volume":"58","author":"T Nagahara","year":"2015","unstructured":"Nagahara, T. et al. Design and synthesis of non-peptide, selective orexin receptor 2 agonists. J. Med. Chem. 58, 7931\u20137937 (2015).","journal-title":"J. Med. Chem."},{"key":"30601_CR17","doi-asserted-by":"crossref","unstructured":"Fujimoto, T. et al. Discovery of TAK-925 as a potent, selective, and brain-penetrant orexin 2 receptor agonist. ACS Med. Chem. Lett. 13, 457\u2013462 (2022).","DOI":"10.1021\/acsmedchemlett.1c00626"},{"key":"30601_CR18","doi-asserted-by":"publisher","first-page":"172794","DOI":"10.1016\/j.pbb.2019.172794","volume":"187","author":"H Yukitake","year":"2019","unstructured":"Yukitake, H. et al. TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice. Pharm. Biochem Be 187, 172794 (2019).","journal-title":"Pharm. Biochem Be"},{"key":"30601_CR19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature14035","volume":"519","author":"J Yin","year":"2015","unstructured":"Yin, J., Mobarec, J. C., Kolb, P. & Rosenbaum, D. M. Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant. Nature 519, 247\u2013250 (2015).","journal-title":"Nature"},{"key":"30601_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nsmb.3183","volume":"23","author":"J Yin","year":"2016","unstructured":"Yin, J. et al. Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors. Nat. Struct. Mol. Biol. 23, 293\u2013299 (2016).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"30601_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.str.2017.11.005","volume":"26","author":"R Suno","year":"2018","unstructured":"Suno, R. et al. Crystal structures of human orexin 2 receptor bound to the subtype-selective antagonist EMPA. Structure 26, 7\u201319.e5 (2018).","journal-title":"Structure"},{"key":"30601_CR22","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1021\/acs.jmedchem.9b01787","volume":"63","author":"M Rappas","year":"2020","unstructured":"Rappas, M. et al. Comparison of orexin 1 and orexin 2 ligand binding modes using X-ray crystallography and computational analysis. J. Med Chem. 63, 1528\u20131543 (2020).","journal-title":"J. Med Chem."},{"key":"30601_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1124\/mol.110.064584","volume":"78","author":"P Malherbe","year":"2010","unstructured":"Malherbe, P. et al. Mapping the binding pocket of dual antagonist almorexant to human orexin 1 and orexin 2 receptors: comparison with the selective OX1 antagonist SB-674042 and the selective OX2 antagonist N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA). Mol. Pharmacol. 78, 81\u201393 (2010).","journal-title":"Mol. Pharmacol."},{"key":"30601_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21087-6","volume":"12","author":"C Hong","year":"2021","unstructured":"Hong, C. et al. Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation. Nat. Commun. 12, 815 (2021).","journal-title":"Nat. Commun."},{"key":"30601_CR25","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41586-018-0219-7","volume":"558","author":"A Koehl","year":"2018","unstructured":"Koehl, A. et al. Structure of the \u00b5-opioid receptor-Gi protein complex. Nature 558, 547\u2013552 (2018).","journal-title":"Nature"},{"key":"30601_CR26","doi-asserted-by":"publisher","first-page":"e0175642","DOI":"10.1371\/journal.pone.0175642","volume":"12","author":"R Nehm\u00e9","year":"2017","unstructured":"Nehm\u00e9, R. et al. Mini-G proteins: novel tools for studying GPCRs in their active conformation. Plos One 12, e0175642 (2017).","journal-title":"Plos One"},{"key":"30601_CR27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ejphar.2011.05.074","volume":"667","author":"D-T Tran","year":"2011","unstructured":"Tran, D.-T. et al. Chimeric, mutant orexin receptors show key interactions between orexin receptors, peptides and antagonists. Eur. J. Pharm. 667, 120\u2013128 (2011).","journal-title":"Eur. J. Pharm."},{"key":"30601_CR28","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/S1043-9471(05)80049-7","volume":"25","author":"JA Ballesteros","year":"1995","unstructured":"Ballesteros, J. A. & Weinstein, H. [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci. 25, 366\u2013428 (1995).","journal-title":"Methods Neurosci."},{"key":"30601_CR29","doi-asserted-by":"publisher","first-page":"e50279","DOI":"10.7554\/eLife.50279","volume":"8","author":"Q Zhou","year":"2019","unstructured":"Zhou, Q. et al. Common activation mechanism of class A GPCRs. Elife 8, e50279 (2019).","journal-title":"Elife"},{"key":"30601_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature14886","volume":"524","author":"W Huang","year":"2015","unstructured":"Huang, W. et al. Structural insights into \u00b5-opioid receptor activation. Nature 524, 315\u2013321 (2015).","journal-title":"Nature"},{"key":"30601_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1021\/acs.chemrev.6b00177","volume":"117","author":"NR Latorraca","year":"2017","unstructured":"Latorraca, N. R., Venkatakrishnan, A. J. & Dror, R. O. GPCR dynamics: structures in motion. Chem. Rev. 117, 139\u2013155 (2017).","journal-title":"Chem. Rev."},{"key":"30601_CR32","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/bph.12324","volume":"171","author":"JP Kukkonen","year":"2014","unstructured":"Kukkonen, J. P. & Leonard, C. S. Orexin\/hypocretin receptor signalling cascades. Brit J. Pharm. 171, 314\u2013331 (2014).","journal-title":"Brit J. Pharm."},{"key":"30601_CR33","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nature10361","volume":"477","author":"SGF Rasmussen","year":"2011","unstructured":"Rasmussen, S. G. F. et al. Crystal structure of the \u03b22 adrenergic receptor-Gs protein complex. Nature 477, 549\u2013555 (2011).","journal-title":"Nature"},{"key":"30601_CR34","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1126\/science.aaw5188","volume":"364","author":"S Maeda","year":"2019","unstructured":"Maeda, S., Qu, Q., Robertson, M. J., Skiniotis, G. & Kobilka, B. K. Structures of the M1 and M2 muscarinic acetylcholine receptor\/G-protein complexes. Science 364, 552\u2013557 (2019).","journal-title":"Science"},{"key":"30601_CR35","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.cell.2020.08.024","volume":"182","author":"K Kim","year":"2020","unstructured":"Kim, K. et al. Structure of a hallucinogen-activated Gq-coupled 5-HT2A serotonin receptor. Cell 182, 1574\u20131588.e19 (2020).","journal-title":"Cell"},{"key":"30601_CR36","doi-asserted-by":"publisher","first-page":"e3001295","DOI":"10.1371\/journal.pbio.3001295","volume":"19","author":"JI Mobbs","year":"2021","unstructured":"Mobbs, J. I. et al. Structures of the human cholecystokinin 1 (CCK1) receptor bound to Gs and Gq mimetic proteins provide insight into mechanisms of G protein selectivity. Plos Biol. 19, e3001295 (2021).","journal-title":"Plos Biol."},{"key":"30601_CR37","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1038\/s41589-021-00841-3","volume":"17","author":"Q Liu","year":"2021","unstructured":"Liu, Q. et al. Ligand recognition and G-protein coupling selectivity of cholecystokinin A receptor. Nat. Chem. Biol. 17, 1238\u20131244 (2021).","journal-title":"Nat. Chem. Biol."},{"key":"30601_CR38","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/nature14663","volume":"524","author":"T Flock","year":"2015","unstructured":"Flock, T. et al. Universal allosteric mechanism for G\u03b1 activation by GPCRs. Nature 524, 173\u2013179 (2015).","journal-title":"Nature"},{"key":"30601_CR39","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature22327","volume":"546","author":"Y-L Liang","year":"2017","unstructured":"Liang, Y.-L. et al. Phase-plate cryo-EM structure of a class B GPCR\u2013G-protein complex. Nature 546, 118\u2013123 (2017).","journal-title":"Nature"},{"key":"30601_CR40","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1021\/cr050263h","volume":"107","author":"A Zhang","year":"2007","unstructured":"Zhang, A., Neumeyer, J. L. & Baldessarini, R. J. Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders. Chem. Rev. 107, 274\u2013302 (2007).","journal-title":"Chem. Rev."},{"key":"30601_CR41","doi-asserted-by":"publisher","first-page":"PR123","DOI":"10.1021\/cr300113a","volume":"113","author":"N Ye","year":"2013","unstructured":"Ye, N., Neumeyer, J. L., Baldessarini, R. J., Zhen, X. & Zhang, A. Update 1 of: Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders. Chem. Rev. 113, PR123\u2013PR178 (2013).","journal-title":"Chem. Rev."},{"key":"30601_CR42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd2760","volume":"8","author":"PJ Conn","year":"2009","unstructured":"Conn, P. J., Christopoulos, A. & Lindsley, C. W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug Disco. 8, 41\u201354 (2009).","journal-title":"Nat. Rev. Drug Disco."},{"key":"30601_CR43","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1002\/anie.201208561","volume":"52","author":"A Biela","year":"2013","unstructured":"Biela, A. et al. Dissecting the hydrophobic effect on the molecular level: the role of water, enthalpy, and entropy in ligand binding to thermolysin. Angew. Chem. Int. Ed. 52, 1822\u20131828 (2013).","journal-title":"Angew. Chem. Int. Ed."},{"key":"30601_CR44","doi-asserted-by":"publisher","first-page":"8806","DOI":"10.1021\/acs.jmedchem.1c00841","volume":"64","author":"D Zhang","year":"2021","unstructured":"Zhang, D. et al. Discovery of arylsulfonamides as dual orexin receptor agonists. J. Med Chem. 64, 8806\u20138825 (2021).","journal-title":"J. Med Chem."},{"key":"30601_CR45","doi-asserted-by":"publisher","first-page":"18059","DOI":"10.1073\/pnas.2002704117","volume":"117","author":"J Hellmann","year":"2020","unstructured":"Hellmann, J. et al. Structure-based development of a subtype-selective orexin 1 receptor antagonist. Proc. Natl Acad. Sci. USA 117, 18059\u201318067 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"30601_CR46","doi-asserted-by":"publisher","first-page":"re15","DOI":"10.1126\/stke.2001.104.re15","volume":"2001","author":"R-P Xiao","year":"2001","unstructured":"Xiao, R.-P. \u03b2-adrenergic signaling in the heart: dual coupling of the \u03b22-adrenergic receptor to Gs and Gi proteins. Sci. Signal 2001, re15\u2013re15 (2001).","journal-title":"Sci. Signal"},{"key":"30601_CR47","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1254\/jphs.92.259","volume":"92","author":"Y Zhu","year":"2003","unstructured":"Zhu, Y. et al. Orexin receptor type-1 couples exclusively to pertussis toxin-insensitive G-proteins, while orexin receptor type-2 couples to both pertussis toxin-sensitive and -insensitive G-proteins. J. Pharmacol. Sci. 92, 259\u2013266 (2003).","journal-title":"J. Pharmacol. Sci."},{"key":"30601_CR48","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/j.cell.2019.04.044","volume":"177","author":"A Inoue","year":"2019","unstructured":"Inoue, A. et al. Illuminating G-protein-coupling selectivity of GPCRs. Cell 177, 1933\u20131947.e25 (2019).","journal-title":"Cell"},{"key":"30601_CR49","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","volume":"92","author":"T Sakurai","year":"1998","unstructured":"Sakurai, T. et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 573\u2013585 (1998).","journal-title":"Cell"},{"key":"30601_CR50","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1126\/science.aaz5346","volume":"367","author":"A Qiao","year":"2020","unstructured":"Qiao, A. et al. Structural basis of Gs and Gi recognition by the human glucagon receptor. Science 367, 1346\u20131352 (2020).","journal-title":"Science"},{"key":"30601_CR51","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/S0021-9258(18)48416-5","volume":"267","author":"E Lee","year":"1992","unstructured":"Lee, E., Taussig, R. & Gilman, A. G. The G226A mutant of Gs alpha highlights the requirement for dissociation of G protein subunits. J. Biol. Chem. 267, 1212\u20131218 (1992).","journal-title":"J. Biol. Chem."},{"key":"30601_CR52","doi-asserted-by":"publisher","first-page":"21752","DOI":"10.1074\/jbc.273.34.21752","volume":"273","author":"BA Posner","year":"1998","unstructured":"Posner, B. A., Mixon, M. B., Wall, M. A., Sprang, S. R. & Gilman, A. G. The A326S mutant of Gi\u03b11 as an approximation of the receptor-bound state. J. Biol. Chem. 273, 21752\u201321758 (1998).","journal-title":"J. Biol. Chem."},{"key":"30601_CR53","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41586-020-2379-5","volume":"584","author":"J Yin","year":"2020","unstructured":"Yin, J. et al. Structure of a D2 dopamine receptor-G-protein complex in a lipid membrane. Nature 584, 125\u2013129 (2020).","journal-title":"Nature"},{"key":"30601_CR54","doi-asserted-by":"publisher","first-page":"163","DOI":"10.7554\/eLife.42166","volume":"7","author":"J Zivanov","year":"2018","unstructured":"Zivanov, J. et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. Elife 7, 163 (2018).","journal-title":"Elife"},{"key":"30601_CR55","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nmeth.4193","volume":"14","author":"SQ Zheng","year":"2017","unstructured":"Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Meth. 14, 331\u2013332 (2017).","journal-title":"Nat. Meth."},{"key":"30601_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsb.2015.11.003","volume":"193","author":"K Zhang","year":"2016","unstructured":"Zhang, K. Gctf: Real-time CTF determination and correction. J. Struct. Biol. 193, 1\u201312 (2016).","journal-title":"J. Struct. Biol."},{"key":"30601_CR57","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jsb.2015.08.008","volume":"192","author":"A Rohou","year":"2015","unstructured":"Rohou, A. & Grigorieff, N. CTFFIND4: Fast and accurate defocus estimation from electron micrographs. J. Struct. Biol. 192, 216\u2013221 (2015).","journal-title":"J. Struct. Biol."},{"key":"30601_CR58","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"30601_CR59","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera\u2014a visualization system for exploratory research and analysis. J. Comput Chem. 25, 1605\u20131612 (2004).","journal-title":"J. Comput Chem."},{"key":"30601_CR60","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1107\/S0907444906022116","volume":"62","author":"K Cowtan","year":"2006","unstructured":"Cowtan, K. The Buccaneer software for automated model building. 1. Tracing protein chains. Acta Crystallogr D. Biol. Crystallogr 62, 1002\u20131011 (2006).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"30601_CR61","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr D. Biol. Crystallogr 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"30601_CR62","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1107\/S2059798319011471","volume":"75","author":"D Liebschner","year":"2019","unstructured":"Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr D. Struct. Biol. 75, 861\u2013877 (2019).","journal-title":"Acta Crystallogr D. Struct. Biol."},{"key":"30601_CR63","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/j.cpc.2010.04.018","volume":"181","author":"M Valiev","year":"2010","unstructured":"Valiev, M. et al. NWChem: A comprehensive and scalable open-source solution for large scale molecular simulations. Comput Phys. Commun. 181, 1477\u20131489 (2010).","journal-title":"Comput Phys. Commun."},{"key":"30601_CR64","doi-asserted-by":"publisher","first-page":"6378","DOI":"10.1021\/jp810292n","volume":"113","author":"AV Marenich","year":"2009","unstructured":"Marenich, A. V., Cramer, C. J. & Truhlar, D. G. Universal solvation model based on solute electron density and on a continuum model of the solvent defined by the bulk dielectric constant and atomic surface tensions. J. Phys. Chem. B 113, 6378\u20136396 (2009).","journal-title":"J. Phys. Chem. B"},{"key":"30601_CR65","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/sj.bjp.0706733","volume":"148","author":"JM Mathiesen","year":"2006","unstructured":"Mathiesen, J. M. & Ramirez, M. T. The metabotropic glutamate receptor 4 is internalized and desensitized upon protein kinase C activation. Br. J. Pharmacol. 148, 279\u2013290 (2006).","journal-title":"Br. J. Pharmacol."},{"key":"30601_CR66","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1074\/jbc.271.1.496","volume":"271","author":"JR Hepler","year":"1996","unstructured":"Hepler, J. R. et al. Functional importance of the amino terminus of Gq\u03b1 (\u2217). J. Biol. Chem. 271, 496\u2013504 (1996).","journal-title":"J. Biol. Chem."},{"key":"30601_CR67","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/bs.mcb.2017.07.012","volume":"142","author":"BA Kumar","year":"2017","unstructured":"Kumar, B. A., Kumari, P., Sona, C. & Yadav, P. N. Chapter 2 GloSensor assay for discovery of GPCR-selective ligands. Methods Cell Biol. 142, 27\u201350 (2017).","journal-title":"Methods Cell Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30601-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30601-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30601-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T07:03:03Z","timestamp":1685602983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30601-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,25]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["30601"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-30601-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,25]]},"assertion":[{"value":"28 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.Y., K.C., R.R., P.L., X.B., J.K.D.B., and D.M.R. declare no competing interests. Y.K., A.P.M., M.S., E.K., A.O., T.K., Y.M., Y.S. and M.F. are current or former employees of Takeda Pharmaceutical Company Limited.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2902"}}